Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes
Authors:
Open Access
- 9 March 2026
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (6) , 769-781.e8
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus NephritisArthritis & Rheumatology, 2025
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeuticsSignal Transduction and Targeted Therapy, 2025
- Systemic Lupus ErythematosusJAMA, 2024
- The use of the E-value for sensitivity analysisJournal of Clinical Epidemiology, 2023
- Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protectionAmerican Journal of Preventive Cardiology, 2023
- Risk of End‐Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort StudyArthritis Care & Research, 2023
- STROBE Reporting Guidelines for Observational StudiesJAMA Surgery, 2021
- Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective AnalysisDiabetes Technology & Therapeutics, 2020
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseasesNature Reviews Rheumatology, 2015